The American Urological Association (AUA) announced that it has updated its guideline for the diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adult patients.

As a result of a 2018 systematic review of recently published studies, AUA modified guideline statement 12 to say clinicians may consider combination therapy with an antimuscarinic agent and beta3-andrenoceptor agonist for patients who are refractory to monotherapy with either of those medications.

“This clinical framework for OAB does not require every patient go through each line of treatment in order, as there are many factors to consider when working with a patient to select the best treatment option,” Sandip Prasan Vasavada, MD, guideline panel member and professor of surgery and urology at the Cleveland Clinic Foundation, said in an AUA press release. “This latest amendment to the guideline reflects recently published studies, including the success of using combination therapy to treat OAB and we are confident it is fully aligned with the latest science on treatments for patients with overactive bladder.”

Reference

AUA announces update to its overactive bladder clinical practice guideline. April 4, 2019 press release.